NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









20Med Therapeutics

20Med Therapeutics

Private
EnschedeHealthcare & Life Scienceshttps://www.20medtx.com/

Last Round

Grant

Feb 2, 2023

Total Funding Raised

$850,000

Company Overview

20Med Therapeutics is a biotechnology company that develops RNA and DNA-based vaccines and therapeutics using a proprietary bio-responsive polymeric nanoparticle platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Advanced Materials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

drug deliverypolymeric nanoparticlesmRNA deliverynon-viral deliveryvaccine thermostabilitygene therapyoligonucleotide therapeuticscold-chain freebioresponsive materialsnanogelintracellular deliverybiotech platformdrug delivery techLNP alternative

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

20Med Therapeutics Comparables

Compare 20Med Therapeutics with similar companies based on industry and business-model similarity.

20Med Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Xanadu Bio
82%
Nanite, Inc.
81%
ACM Biolabs
80%

20Med Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 2, 2023
GrantJul 24, 2019
SeedNov 2, 2017

20Med Therapeutics Investors

Notable investors and investment history

20Med Therapeutics investors
InvestorRounds
CEPIGrant
European CommissionGrant
Twente Technology FundSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 23, 2023

    Grew 21% QoQ, from 14 to 17 employees.

  • Nov 2, 2017

    Twente Technology Fund and innovatiefonds-twente participated in the round.

20Med Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

20Med Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about 20Med Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersEnschede
Employee Range4
Year Founded2011
Last FundingFeb 2, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.